The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement
N-Butyldeoxynojirimycin (NB-DNJ, miglustat 'Zavesca') is an orallyactive iminosugar which inhibits the biosynthesis of macromolecular substrates that accumulate pathologically in glycosphingolipidoses. Clinical trials of NB-DNJ in patients with Gaucher's disease demonstrate the therapeutic potential of such substrate inhibitors in the glycolipid storage disorders. However, macrophage-targetted enzyme replacement using intravenous mannose-terminated human glucocerebrosidase (imiglucerase, Cerezyme) is highly effective in ameliorating many of the manifestations of Gaucher's disease and is a treatment in widespread use. Given that imiglucerase and miglustat are now both licensed for the treatment of Gaucher's disease, there is a need to review their therapeutic status. Here the treatment of type 1 (non-neuronopathic) Gaucher disease is evaluated with particular reference to the emerging role of oral N-butyldeoxynojirimycin (miglustat) as a substrate-reducing agent. This position statement represents the consensus viewpoint of an independent international advisory council to the European Working Group on Gaucher Disease.
Unable to display preview. Download preview PDF.
- Aerts JMFG, Hollak CEM (1997) Plasma and metabolic abnormalities in Gaucher's disease. In: Zimran A, ed. Baillikre's Clinical Haematology: Gaucher's Disease, Vol. 10. London: Bailliere-Tindall, 691–709.Google Scholar
- Beutler E, Grabowski GA (2001) Gaucher disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635–3668.Google Scholar
- Brady RO (1978) Glucosyl ceramide lipidosis: Gaucher's disease. In Stanbury JB, Wyngaarden JB, Fredickson DS, eds; The Metabolic Basis of Inherited Disease, 4th edn. New York: McGraw-Hill: 731–746.Google Scholar
- Cox TM, Schofield JP (1997) Gaucher's disease: clinical features and natural history. In: Zimran A, ed. Bailliere's Clinical Haematology: Gaucher's Disease, Vol. 10. London: Baillere-Tindall, 657–689.Google Scholar
- Elstein D, Dwek A, Attias D, et al (2002). A randomised study of OGT 918 as an oral therapy in patients previously treated with enzyme replacement for type 1 Gaucher disease. Presented at the Fifth Workshop of the European Working Group on Gaucher Disease, Prague, 1 4 May 2002.Google Scholar
- Fischl MA, Resnick L, Coombs R, et al (1994) The safety and efficacy of combination N-butyldeoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200 500 CD4 cells/mm3. J Acquired Immune Defic Syndr 7: 139–147.Google Scholar
- Grabowski GA, Horowitz M (1997) Gaucher's disease: molecular, genetic and enzymological aspects. In Zimran A, ed. Baillikre's Clinical Haematology: Gaucher's Disease. London: Baillere-Tindall, 635–656.Google Scholar
- Hollak CEM, Mass M, Akkerman E, den Heeten A, Aerts JMFG (2001) Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27(6): 1005–1012.PubMedCrossRefGoogle Scholar
- Inokuchi J, Radin NS (1987) Preparation of the active isomer of 1-phenyl-2-decanoyl-amino-3-morpholino-l-propanol inhibitor of murine glucocerebroside synthetase. J Lipid Chem 28: 565–571.Google Scholar
- Knudson AG, Kaplan WD (1962) Genetics of the sphingolipidoses. In Aronson SM, Volk BW eds; Cerebral Sphingolipidoses. New York: Academic Press, 395.Google Scholar
- Levy-Lahad E, Zimran A (1997) Gaucher's disease: genetic counselling and population screening. In Zimran A, ed. Bailliere's Clinical Haematology: Gaucher's Disease. London: Baillere-Tindall, 779–793.Google Scholar
- Tierney M, Pottage J, Kessler H, et al (1995) The tolerability and pharmacokinetics of N-butyldeoxynojirimycin in patients with advanced HIV disease (ACTG 100): the AIDS Clinical Trial Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J Acquired Immune Defic Syndr Hum Retrovir 10: 549–553.CrossRefGoogle Scholar
- Zimran A, Kay A, Gelbart T, et al (1992) Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients. Medicine (Baltimore) 71(6): 337–353.Google Scholar